Reduced paraoxonase 1/arylesterase activity and its post-therapeutic increase in obstructive sleep apnea syndrome: A preliminary study

Clinica Chimica Acta

Volumn 395, Issue 1-2, 2008, Pages 184-185

  Kotani, Kazuhiko ^a   Kimura, Satoshi ^d   Tsuzaki, Kokoro ^a   Sakane, Naoki ^a   Komada, Ichiro ^b   Schulze, John ^c   Gugliucci, Alejandro ^c  

^a NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^b Social Insurance Shiga Hospital   (Japan)

^c TOURO UNIVERSITY CALIFORNIA   (United States)

^d SHOWA UNIVERSITY NORTHERN YOKOHAMA HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE;

ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CORRELATION COEFFICIENT; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; HYPOXIA; LETTER; OXIDATIVE STRESS; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PROTEIN FUNCTION; SLEEP APNEA SYNDROME;

ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; CONTINUOUS POSITIVE AIRWAY PRESSURE; ENZYME ACTIVATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SLEEP APNEA, OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 47649115894     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.04.023     Document Type: Letter

References (12)

1. Shahar E., Whitney C.W., Redline S., et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 163 (2001) 19-25
2. Lavie L., Vishnevsky A., and Lavie P. Evidence for lipid peroxidation in obstructive sleep apnea. Sleep 27 (2004) 123-128
3. Mackness M.I., Durrington P.N., and Mackness B. The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention. Am J Cardiovasc Drugs 4 (2004) 211-217
4. Aviram M., and Rosenblat M. Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr Opin Lipidol 16 (2005) 393-399
5. Tan K.C., Chow W.S., Lam J.C., et al. HDL dysfunction in obstructive sleep apnea. Atherosclerosis 184 (2006) 377-382
6. Börgel J., Sanner B.M., Bittlinsky A., et al. Obstructive sleep apnoea and its therapy influence high-density lipoprotein cholesterol serum levels. Eur Respir J 27 (2006) 121-127
7. Kapuniai L.E., Andrew D.J., Crowell D.H., and Pearce J.W. Identifying sleep apnea from self-reports. Sleep 11 (1988) 430-436
8. Iesato K., Tatsumi K., Saibara T., et al. Decreased lipoprotein lipase in obstructive sleep apnea syndrome. Circ J 71 (2007) 1293-1298
9. Mackness B., Quarck R., Verreth W., Mackness B., and Holvoet P. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler Thromb Vasc Biol 26 (2006) 1545-1550
10. Kim N.S., Kang K., Cha M.H., et al. Decreased paraoxonase-1 activity is a risk factor for ischemic stroke in Koreans. Biochem Biophys Res Commun 364 (2007) 157-162
11. Coughlin S.R., Mawdsley L., Mugarza J.A., Calverley P.M., and Wilding J.P. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J 25 (2004) 735-741
12. Culebras A. Cerebrovascular disease and the pathophysiology of obstructive sleep apnea. Curr Neurol Neurosci Rep 7 (2007) 173-179